Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ: CPRX )

20.98 +0.11 (+0.50%)
Streaming Delayed Price Updated: 12:17 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a CANSLIM stock.
A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for Growth Investing Strategies? 
Via Chartmill
Looking for growth without the hefty price tag? Consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced... 
Via Chartmill
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock?
Based on a technical and fundamental analysis of NASDAQ:CPRX we are exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout. 
Via Chartmill
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing?
A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing? 
Via Chartmill
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
The drugmaker confirmed there's a strong market for two of its treatments. 
Via The Motley Fool
Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Why NASDAQ:CPRX qualifies as a high growth stock.
A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects. 
Via Chartmill
Unlocking the Growth Potential of NASDAQ:CPRX.
A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
Exploring NASDAQ:CPRX's high growth characteristics.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why. Full fundamental and technical analysis of (NASDAQ:CPRX). 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
CATALYST PHARMACEUTICALS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:CPRX showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
Investors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced.
Based on Fundamental Analysis it can be said that NASDAQ:CPRX is a growth stock which is not overvalued. 
Via Chartmill
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.
Based on a technical and fundamental analysis of NASDAQ:CPRX we can say: CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout. 
Via Chartmill
NASDAQ:CPRX: good value for what you're paying.
Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock
Via Benzinga
Unlocking the Growth Potential of NASDAQ:CPRX.
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s CANSLIM characteristics. 
Via Chartmill
Why NASDAQ:CPRX qualifies as a high growth stock.
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
While growth is established for NASDAQ:CPRX, the stock's valuation remains reasonable.
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Unlocking the high Growth Potential of NASDAQ:CPRX.
Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s high Growth Prospects. 
Via Chartmill
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
NASDAQ:CPRX, an undervalued stock with good fundamentals.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86. 
Via Investor's Business Daily
NASDAQ:CPRX, a growth stock which is not overvalued.
NASDAQ:CPRX is not too expensive for the growth it is showing. 
Via Chartmill
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Should you consider NASDAQ:CPRX for growth investing?
Exploring growth characteristics of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
One of Catalyst's key products has protection against a knockoff from Teva until 2035. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.